GILD News and Press, Gilead Sciences Inc. From 06/07/24

2024-06-07 15:00:58 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Citi – ...

2024-06-06 12:38:52 ET Summary FibroGen, Inc. top-line data from the phase 2/3 PanCAN Precision Promise study, using pamrevlumab for the treatment of patients with metastatic pancreatic cancer, expected mid-2024. Topline data from the phase 3 LAPIS study, using pamrevlumab for the...

2024-06-06 10:47:18 ET More on 2seventy bio 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...

- Phase 2b Data Presented at EASL and Published in NEJM Show Potential for Bulevirtide 10 mg in Combination with Pegylated Interferon Alfa-2a as Finite Therapy for People with Chronic Hepatitis Delta - - Data Published in NEJM Demonstrate 46% of Patients Taking Bulevirtide 10 mg with ...

2024-06-05 14:05:27 ET Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Presentation ...

NORTHAMPTON, MA / ACCESSWIRE / June 5, 2024 / Emma was a 28-year-old nursing student when she was diagnosed with triple-negative breast cancer. She had always wanted children and, once she learned that her treatment could affect her fertility, she found herself needing to make a quick family pla...

- Positive Results from Two-year Interim Analysis Includes Participants from Phase 3 RESPONSE Study and are Highly Consistent with One-year Interim Analysis - - Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Participants with Moderate to Severe Symptoms - ...

2024-06-03 14:01:03 ET More on Gilead Sciences, Arcus Biosciences Gilead Sciences: Seriously Undervalued At Peak Pessimism Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO ...

-- After More Than Four Years of Follow-up in the Pivotal ZUMA-3 Study, Median Overall Survival (OS) was 26 Months and the OS Rate was 40% at 48 Months -- -- Survival Benefit was Seen Regardless of Age, Prior Treatment or Subsequent Allogeneic Stem Cell Transplant Status -- ...

-- At Median Follow-Up of 24.2 Months, No Additional Risks of Adverse Events Related to Yescarta Were Observed -- -- Findings Also Suggest Efficacy Trend with Median Progression-Free Survival and Durability of Response of More Than a Year -- -- Data Presented Orally at the...